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ABSTRACT: Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative disorder caused 
by CAG triplet repeats expansion in exon 1 of the Huntingtin gene (HTT). In China, HD is considered to have a 
low prevalence. The goal of this study was to describe the clinical characteristic and genetic profiles of HD in a 
Chinese cohort. A total of 322 individuals with expanded CAG repeats were consecutively recruited from the 
neurologic clinics of three medical centers in Southeastern China between 2008 and 2018. Among them, 80 were 
pre-symptomatic mutation carriers and 242 were symptomatic patients. The mean age at onset (AAO), defined 
here as the age at motor symptom onset, of the 242 manifest HD individuals was 40.3 ± 11.9 years and the mean 
CAG repeat length was 46.1 ± 7.5 in the group of symptomatic patients. Initial symptoms were abnormal 
movements in 88.8% of the patients with psychiatric symptoms in 6.2%, cognitive impairment in 3.3% and others 
in 1.7%. The AAO of motor was negatively correlated with the CAG repeat length in an exponential regression 
analysis (R 2 = 0.74, P<0.001). Analysis of 46 parent-child pairs showed that the CAG repeat length was longer 
in the offspring group (45.8 ±7.6) than in the parent group (43.8 ±3.0) (p=0.005). Overall, this study provides 
clinical and genetic profiles in a cohort of Chinese patients with HD, which should contribute to a better 
understanding of this disorder. 
 
Key words: Huntington’s disease, Chinese population, phenotype, genotype 
 
 
 
Huntington’s disease (HD) is an autosomal dominant 
inherited neurodegenerative disorder characterized by 
movement disorder (i.e. chorea and dystonia), cognitive 
decline and psychiatric symptoms. HD is caused by CAG 
triplet repeats expansion in the exon 1 of the Huntingtin 
gene (HTT) [1]. Symptoms usually begin insidiously at 
mid-adult life, and inexorably worsen until patients’ 
premature death, usually in about 15-20 years after the 
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motor symptom onset [2]. In general population, the 
normal HTT gene contains a sequence of 6-26 CAG 
repeats. Individuals who inherit an expanded CAG repeat 
of 40 or more will manifest the disease with a complete 
penetrance, whereas those who inherited 36-39 CAG 
repeats may be affected with milder penetrance. Although 
the intermediate alleles (27-35 CAG repeats) are 
considered not to be in a pathogenic range, they are 
unstable alleles and may expand or contract during the 
germline transmission [3].  
HD prevalence is about 4-10 per 100,000 in the 
Caucasian populations but varies greatly between ethnic 
origins [4]. Among East Asians and South Africans, the 
prevalence of HD is reportedly to be only 0.1-1 per 
100,000 [5-7]. Recently, an epidemiological study found 
the average annual incidence rate of HD in Taiwan China 
to be 0.1/100,000 [8]. In the absence of a nationwide 
epidemiological study in mainland China, the prevalence 
of HD in the Han Chinese population remains unknown. 
Further, there is a paucity of clinical phenotype 
description in this population. 
In this study, we aim to provide a description of the 
clinical characteristics, genetic profile in a cohort of Han 
Chinese HD patients and gene carriers. We compared our 
findings with those reported in other ethnic populations 
around the world. These data are of great significance in 
guiding the clinical practice, especially in practical 
diagnostic process and genetic counselling. Moreover, the 
clinical and genetic studies of HD in different ethnic 
populations may provide new insights into this disorder. 
 
MATERIALS AND METHODS 
 
Subjects 
 
A total of 322 individuals with expanded triplet repeats 
(80 pre-symptomatic mutation carriers and 242 manifest 
HD) from 238 families were consecutively recruited from 
the neurologic clinics of three medical centers (Second 
Affiliated Hospital of Zhejiang University School of 
Medicine, First Affiliated Hospital of Fujian Medical 
University and Huashan Hospital affiliated to Fudan 
University) in China between February 2008 and March 
2018. HD diagnosis was made by at least two senior 
neurologists according to patients’ clinical manifestations 
in the context of positive HTT genetic tests. Predictive 
tests were performed in relatives as they requested after 
appropriate genetic counsel. Pre-symptomatic mutation 
carriers refer to those who show no motor signs and no 
other subjective symptoms or clinical sign which would 
be typical for HD. Comprehensive demographic and 
clinical data, including medical and psychiatric history, 
HD family history, and current medications were 
collected from the participants. All participants signed the 
informed consent form, or if the participants were unable 
to provide consent, an authorized representative provided 
the consents on their behalf. The study was approved by 
local Ethics Committees (i.e. Institutional Review Board) 
for medical research at three participating hospitals.  
The age at onset (AAO) is defined by the age when 
motor signs or symptoms occur. Homozygous HD gene 
carriers refers to individuals with two expanded alleles. 
 
Genetic analysis of the HTT gene 
 
Genomic DNA was extracted from peripheral blood 
treated by ethylene diamine tetraacetic acid (EDTA). 
Genetic testing for HTT gene was performed using the 
method previously reported [9]. Briefly, the primers of 
HTT (F: 5′ -CAGAGCCCCATT CATTGCC-3′ and R: 5′-
TGAGGAAGCTGAGGA GGC-3′) were used to amplify 
the exon 1 in the CAG polymorphic region of the HTT 
gene. Polymerase chain reaction (PCR) amplicons were 
electrophoresed on a 1.5% agarose gel at 180V for twenty 
minutes to determine the primary HTT results. Then the 
length of CAG repeats was determined by Sanger 
sequencing. 
 
Statistical analyses 
 
Demographic, clinical characteristics and genetic profile 
were analyzed using descriptive statistics. The data 
distributions of AAO and CAG were assessed by 
Kolmogorov-Smirnov test. AAO was normally 
distributed yet the CAG was distributed with a skew. For 
comparison between two continuous variables, T tests, 
Wilcoxon tests or Mann-Whitney were used as 
appropriate. ANOVA was used for comparison between 
multi-group. Correlation was calculated by Pearson or 
Fisher exact Chi-Square when appropriate. Statistical 
analysis was conducted using SPSS 20.0. The p-value less 
than 0.05 was considered statistically significant. 
 
Table 1. The profile of persons with HD in our cohort. 
 
  Number 
Patients 322 
Manifest HD  242 
Premanifest HD  80 
Family  238 
Clear transmit mode 178 
      Paternal/ Maternal 95/83 
Uncertain family history 34 
Unknown family history 26 
CAG available 309 
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Figure 1. The geographical distribution of HD patients. Most patients were from Southeast China. 
 
RESULTS 
 
Population features 
 
As shown in Table 1, among the 322 persons with 
abnormal repeats from 238 families, 242 (131 males and 
111 females) were symptomatic patients while 80 (35 
males and 45 females) were pre-symptomatic mutation 
carriers. To control against bias created by the presence of 
several family members, the index case from each family 
was included to calculate the transmission mode. Among 
238 families, 178 had clear transmission mode (95 
paternal and 83 maternal inheritance) and 34 denied their 
parents had any known chorea-like movements and 
information from the remaining 26 was lacking. Data on 
CAG repeat numbers was obtained from 309 subjects. 
DNA was missing from the remaining 13 persons. The 
mean age at genetic test was 29.9 ± 11.7 years (range 1-
66 years) in the pre-symptomatic carriers with their mean 
number of CAG repeats of 44.2 ± 4.0 (range 37-59). The 
majority of the families were from Southeastern China 
(Fig. 1). The Unified Huntington’s Disease Rating Scale 
(UHDRS) was applied to assess the motor, cognitive and 
psychiatric symptoms. Age at onset was assessed in a 
structured interview and by use of all clinical reports. 
Assessments were performed by trained neurologists. 
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Table 2. Age at motor onset and CAG repeats among juvenile HD, adult HD and elder HD. 
 
  AAO (years)         CAG  
Age at diagnosis 
(years) 
DOD (years) 
  Mean (SD) Range Mean (SD) Range Mean (SD) Range Mean (SD) Range 
Total (n=242) 40.3 (11.9) 4-71 46.1 (7.5) 38-104 45.7 (12.4) 7-83 5.4 (4.3) 0.25-30 
   male 39.7 (12.8) 8-71 46.5 (8.0) 39-104 45.1 (13.4) 10-83 5.5 (4.4) 0.25-27 
   female 41.0 (11.0) 4-60 45.6 (6.9) 38-92 46.4 (11.2) 7-68 5.4 (4.2) 0.25-30 
Juvenile HD (n=15) 14.5 (4.8) 4-20 67.0 (16.8) 46-104 20.9 (9.3) 7-42 6.4 (6.9) 1-27 
   male 14.8 (4.2) 8-20 65.8 (18.6) 46-104 21.2 (10.2) 10-42 6.4 (8.3) 1-27 
   female 14.0 (6.2) 4-19 69.0 (14.8) 56-92 20.4 (8.3) 7-28 6.4 (3.3) 3-10 
Adult HD (n=220) 41.4 (9.4) 21-59 44.9 (3.6) 39-58 46.7 (10.1) 23-68 5.3 (4.1) 0.25-30 
   male 40.7 (9.8) 21-59 45.2 (3.5) 39-58 46.1 (10.6) 23-68 5.4 (3.9) 0.25-23 
   female 42.0 (9.1) 21-59 44.6 (3.4) 40-54 47.3 (9.5) 26-68 5.3 (4.3) 0.25-30 
Elderly-onset HD (n=7) 63.7 (4.8) 60-71 39.3 (0.9) 38-41 69.6 (6.7) 63-83 5.8 (3.2) 3-12 
   male 63.7 (4.9) 60-71 39.3 (0.9) 38-41 70.8 (7.7) 63-83 5.6 (3.8) 3-12 
   female 60 60 38.5 38-39 66.5 65-68 6.5 5-8 
 
DOD: Duration from onset to diagnosis 
 
Clinical spectrum 
 
Age at onset 
 
Reliable data on AAO were available in 242 HD patients. 
The mean motor AAO was 40.3 ± 11.9 (range 4-71) years 
(Table 2) (Fig. 2A). The average age at diagnosis was 45.7 
± 12.4 (range 7-83) years with an average diagnostic delay 
of 5.4 years. Fifteen (6.2%) had a juvenile onset with a 
mean AAO of 14.5 ± 4.8 (range 7-20) years, and 7 (2.9%) 
had an old age onset with a mean AAO of 63.7 ± 4.8 
(range 60-71) years. The other 220 patients (90.9%) had 
adult onset with an average mean AAO of 41.4 ±9.4 
(range 21-59) years. (Table 2). 
 
Spectrum of initial symptoms 
 
Among the 242 symptomatic gene carriers, 215 first 
presented with motor signs (88.8%, 117 males and 98 
females) and 27 (11.2%, 14 males and 13 females) 
presented with non-motor symptoms and developed 
motor disorder later. Chorea was the most frequent motor 
sign (n=195, 80.6%). Other types of motor symptoms 
included ataxia (n=7, 2.9%), gait instability (n=9, 3.7%), 
parkinsonism (n=1, 0.4%), tics (n=1, 0.4%), tremors (n=1, 
0.4%) and dystonia (n=1, 0.4%). Eight patients (3.3%, 7 
males and 1 females) had cognitive impairment first, of 
whom 5 with memory decline and 3 with intellectual 
decline. Fifteen subjects (6.2%, 4 males and 11 females) 
had psychiatric and behavioral symptoms, including 
agitation (n=9, 3.7%), depression (n=5, 2.1%) and 
psychosis (n=1, 0.4%). In addition, two patients had 
mixed psychiatric and cognitive impairment at onset and 
one patient had concurrent movement disorder and 
cognitive decline. Finally, one juvenile patient presented 
with seizure as initial symptom (Fig. 2B). Gender had a 
significant different distribution in motor symptoms 
group vs psychiatric symptom group (p=0.04), or 
cognitive symptom group vs psychiatric symptom group 
(p=0.01) as females had a higher frequency in psychiatric 
symptom group compared with the other groups. 
However, there was no difference for gender between 
motor and cognitive groups (p=0.08). 
 
Duration of disease 
 
Data of 97 deceased HD patients from 238 families were 
analyzed to estimate the duration of disease. Seven of 
them died by accident (n=2), suicide (n=2), cerebral 
hemorrhage (n=2) or because of esophageal cancer (n=1, 
at the age of 62). Hence, these seven patients were not 
included in the further analysis of disease duration.  
As shown in Table S1, the mean duration of disease 
was 13.3 ± 6.3 (range 6-53) years defined by the mean 
AAO (42.9 ± 10.4 years, range 21-70 years) and mean age 
at death (56.2 ± 11.1 years, range 38-83 years). The 
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median duration of disease was 11 years. To examine 
whether duration of disease was related to AAO, we 
divided participants into three groups: 20-39 years, 40-59 
years and 60 years and older. There was no difference 
between these three groups (p=0.50) with a mean disease 
duration of 14.1 ± 8.6, 13.3 ± 5.0 and 11.6 ± 2.1 years, 
respectively. There was no effect of gender on duration of 
survival (p=0.71).  
 
 
 
Figure 2. Clinical and genetic features of Chinese patients with HD. A) Frequency distribution of age at onset 
(AAO) in Chinese HD patients (n=242). The AAO occurred mainly on 40 years of age. B) Spectrum of manifest HD 
with initial symptom (n=242). Chorea was the most frequent initial symptom in manifest HD, accounting for 80.6%. 
The others were atypical motor symptom and cognitive or psychiatric symptom. C) Frequency distribution of CAG 
repeats number with normal and expanded range in affected individuals with HD (n=306). D) Relationship between 
AAO and number of CAG repeats on the larger allele of HTT gene (n=242). The CAG repeats could explain 
approximately 74% of variance in AAO. 
Atypical HD patients 
 
Juvenile HD(JHD) 
 
Fifteen had juvenile onset (mean 14.5 ± 4.8 years, range 
4- 20 years) with a mean CAG value of 67.0 repeats 
(Table S2). Four cases had been reported previously [10]. 
The initial symptoms of these patients were variable, 
including gait instability (n=4), chorea (n=4), intellectual 
decline (n=2), tics (n=1), tremor (n=1), depression (n=1) 
and dystonia (n=1), paroxysmal seizure (n=1). Three 
cases had no family history. Inheritance was paternal in 9 
cases (75%) and maternal in 3 (25.0%). Diagnostic delay 
in JHD patients was 6.4±6.9 (range 1-27) years (Table 2). 
 
Elder HD 
 
Seven patients developed symptoms at the age of 60 years 
or older (mean 63.7 ± 4.8 years, range 60-71 years) (Table 
S3). Six had chorea as their initial symptoms and the other 
one had depression five years prior to the onset of chorea. 
Nearly all elder HD patients complained of memory 
decline, some also had dysarthria and irritability. Four 
(66.7%) had paternal and 2 (33.3%) maternal inheritance, 
whereas one had unknown family history. Expanded CAG 
triplet number was relatively small (mean 39.3 ± 0.9, 
range 38-41) (Table 2). Diagnostic delay was 5.8 ± 3.2 
years.  
 
Homozygous HD 
 
Three homozygotes for elongated CAG repeats were 
found in our cohort (Table S4). One was reported in 2012 
as first homozygous HD (asymptomatic individual) in 
China with CAG repeats of 37/42 [11]. Two additional 
cases were subsequently found with CAG repeats of 36/47 
and 37/56, respectively. The reported female  (CAG= 
37/42) [11] was still asymptomatic at 48 years of age (in 
2018). The second patient with 37/56 CAG repeats 
suffered from developmental delay and intellectual 
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decline starting at 14 years old. Five years later, she 
developed chorea and gait instability. The third one 
(CAG=36/47) first presented with chorea at the age of 40 
years. Afterwards, he developed memory decline at 44 
years, and irritability, dysarthria and dysphagia 4 years 
later. For the three homozygotes, the mean CAG repeat 
length of the longer allele was 48.3 ± 7.1, ranging from 42 
to 56 repeats. The mean AAO and diagnostic delay was 
29.5 ± 14.8 years and 6.5 ± 4.9 years (n=2), respectively.  
 
 
Table 3. Median AAO for each number of CAG repeats in Chinese patients and Dutch patients. 
 
CAG Repeats 
Chinese cohorts (n=232)   Dutch cohort (n=755) 
No. of patients Median AAO (y) 95%CI   No. of patients Median AAO (y) 95% CI 
<=40 13 60 59-62   21 68 55-81 
41 19 50 45-53   28 65 58-72 
42 32 50.5 47-52   90 64 60-68 
43 32 49.5 44-49   80 60 56-64 
44 27 42 40-44   101 55 52-58 
45 22 39.5 37-41   104 50 47-53 
46 17 38 33-40   100 45 43-47 
47 14 35.5 32-42   63 41 39-43 
48 13 33 31-39   50 37 35-39 
49 9 32 26-45   34 38 36-40 
50 5 31 20-39   19 34 30-38 
51 2 29 4-54   8 33 27-39 
52 5 28 22-34   11 29 19-29 
>=53 22 19.5 16-23   46 23 20-26 
 
CI: Confidence Interval. Y: years 
 
Distribution and instability features of CAG repeats 
 
Data on CAG repeat numbers were available for 309 
persons with HD. The three homozygotes mentioned 
above were excluded. The range of triplet repeats in the 
normal allele was 11-26 (mean 17.6 ± 1.6) while in the 
expanded allele, the range was 37-104 (mean 45.6 ± 6.9) 
(Fig. 2C).  
To analyze the CAG instability during the germline 
transmission, we selected 46 parent-child pairs from our 
cohort, including 23 father-child pairs from 23 families 
and 23 mother-child pairs from 20 families (as one mother 
had three children). The gender of the affected parent was 
an important factor affecting the CAG repeats instability. 
The mean CAG repeat number was 43.4 ± 3.3 in father 
group and 46.4 ± 10.4 in corresponding child group, 
expanding by 3.0 ± 7.9 repeats during father-child 
transmission. In mother-child transmission, the CAG 
expanded by 0.9 ± 2.6 repeats with the CAG repeat 
number of 44.3 ± 2.7 in the mother group and 45.2 ± 3.2 
in the corresponding child group. There was a difference 
in the father-child transmission (p=0.014) but not in the 
mother-child transmission (p=0.145). By adding together, 
the CAG repeat length was more significantly longer in 
the offspring group (45.8 ± 7.6) than the parent group 
(43.8 ± 3.0) (p=0.005). 
As shown in Table S5, on HD chromosomes, 
intergenerational CAG changes occurred in 71.7% 
(33/46) of meiosis, with contraction accounting for 23.9% 
(11/46) and expansion for 47.8% (22/46). In the 
remaining 28.3% (13/46) intergenerational transmissions, 
the CAG number was unchanged. Among 22 expanded 
transmissions, only two (9.1%) transmission expanded 
greater than 7 repeats and they were both paternal 
inheritances. The expansion of CAG repeats ranged from 
1 to 37 whereas contraction ranged from -3 to -1. Paternal 
transmitted mutant HTT alleles showed similar proportion 
compared with the maternal transmitted ones. 
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Table 4. The number of CAG repeats, AAO and initial symptoms among different countries. 
 
Genetic and clinical features  Mainland Thai [14] Dutch [12] Korean [17] Mexican [16] African [6] 
Expanded CAG Mean 46.1 43.5 46.0 45.4 47.2 44.5 
 SD 7.5 3.0 4.0 4.7 5.4 4.0 
 Range 38-104 39-48 39-71 40-58 37-106 37-57 
P value  / 0.15 0.80 0.58 0.01* 0.21 
AAO (years) Mean 40.3 37.8 47.0 46.5 37.4 N 
 SD 11.9 8.3 15.0 12.7 12.9 N 
 Range 4-71 27-58 4-86 24-69  2-78   N 
P value  / 0.38 <0.001* 0.004* 0.002* / 
Initial symptom Motor 88.8% N N 89%# 53.0% N 
 Behavior 6.2% N N 36%# 30.0% N 
  Cognition 3.3% N N 28%# 3.5% N 
Cohort number  242 18 614 36 691 37 
 
N: means the article didn't provide. *P value was calculated when compared our cohort data with other countries’. 
#: The article of Korea counted initial symptom by first visit 
Correlations between CAG, AAO and initial symptoms 
 
Correlations between the AAO, CAG and initial 
symptoms were assessed in 242 cases. To explore whether 
CAG repeat length and AAO differed with respect to 
initial symptoms, we divided patients into motor, 
cognitive and psychiatric groups. The CAG repeat 
number was larger in cognitive group (52.8 ± 11.6) than 
motor group (46.0 ± 7.4) (p=0.03) and psychiatric group 
(44.4 ± 6.3) (p=0.02). Accordingly, the AAO of cognitive 
group (25.1 ± 9.1 years) was earliest compared with motor 
group (40.5 ± 11.8 years) (p=0.0003) and psychiatric 
group (40.2 ± 11.1 years) (p=0.0035). This suggested that 
patients presented with cognitive impairment first had 
larger CAG number and earlier AAO. Further, we found 
chorea become more predominant with the increasement 
of AAO, from 26.7% (4/15) in JHD, 83.6% (184 in 220) 
in adult HD to 85.7% (6 in 7) in elder HD. 
The AAO was inversely correlated with the 
expanded CAG repeat number (p<0.0001), and the CAG 
repeat lengths accounted for up to 74% of the variance in 
AAO (r= -0.86, R2 = 0.74) using the exponential 
regression analysis (Fig. 2D). We then separately tested 
their correlation in juvenile HD, adult HD and elder HD, 
and the R2 was 0.63, 0.49, and 0.05, respectively. Strong 
associations were detected both in juvenile HD and adult 
HD (both p< 0.001). However, no correlation was found 
between CAG repeats and AAO in elder HD (p = 0.31). 
This indicated that the AAO of elder HD was not affected 
by the CAG repeat lengths. 
To predict the AAO more accurately, we divided 
patients into groups according to the number of CAG 
repeats and calculated each median AAO. We then 
compared our result with that of Dutch population (Table 
3) [12]. Median AAO in Chinese population was earlier 
than that in Dutch population by each number of CAG 
repeats.  
 
DISCUSSION 
 
Previous studies have suggested that the length of CAG 
repeats in normal HTT chromosomes is associated with 
the prevalence of HD in distinct populations. In a 
population with higher prevalence of HD, the size of 
normal CAG repeats was generally larger [13]. Our study 
showed that the mean CAG repeats of normal allele was 
17.6 ± 1.6 (range 11-26), which is lower than in the 
European population (18.4 ± 3.7, range 8-35, n=479, 
p<0.001) [14]. Of note, normal alleles and intermediate 
alleles in the present study are limited to those determined 
in clinical samples of HD, which may result in an 
ascertainment bias. In our previous study, 483 healthy 
Chinese controls were sequenced in the HTT gene region 
and the mean CAG repeat number was 18.9 ± 2.57 (range 
9-35) as well as the frequency of intermediate alleles was 
2.5% (24/966) [15]. 
The size of CAG triplet on expanded chromosomes 
was within a range of 38 to 104 (mean 46.1 ± 7.5) and the 
mean AAO was 40.3 ± 11.9 (range 4-71) years (Table 4). 
Mexicans [16] had longer CAG length (47.2 ± 5.4, n=691) 
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than in our cohort. Accordingly, they had earlier AAO 
(37.4 ± 12.9 years) (p=0.002). However, Korean and 
Dutch population had similar CAG length (45.4 ± 4.7, 
n=36 [17]; 46.0 ± 4.0, n=614 [12]) to our cohort (p=0.6, 
0.8, respectively), but their AAO was later than in our 
cohort with Korean population (46.5 ± 12.7 years) 
(p=0.004) and Dutch population (47.0 ± 15.0 years) 
(p<0.001). This may be caused by genetic differences 
with distinct modifiers present in one ethnic population 
but not in the other. The comparison of CAG length and 
AAO is shown in Table 4. 
 The negative correlation between CAG repeat 
length and AAO has been found in many studies in 
different populations and confirmed here again [12, 16]. 
In our cohort, 74% of the variation for AAO could be 
explained by the CAG repeat number, which is higher 
compared with a Belgian cohort (50.4%) [18] and a 
Venezuelan cohort (72%) [19]. This indicates that other 
genetic and environmental factors also contribute to the 
remaining variation of AAO. A study on the monozygotic 
twins also suggested that different living conditions and 
individual habits might influence AAO [20]. 
We then analyzed various onset symptoms and found 
that the symptoms were quite diverse in juvenile onset 
HD. However, in adult HD and elder HD, the onset 
symptoms were relatively simple, usually including 
chorea-like symptoms. This suggests that larger CAG 
repeats (generally >60) cause initial symptoms of great 
variety. Movement symptoms were the predominant 
initial symptoms among Chinese HD patients (89%), 
Korean patients (89%) [17], American (69%) [21] and 
Mexican (53%) [16]. Notably, there were only 23 (9.5%) 
patients whose initial symptoms were cognitive decline or 
psychiatric symptoms in our study. This was much lower 
than previously reported, estimated at approximately 33% 
in patients with Mexican origin [16].  
In our cohort median duration of disease was 11 years, 
which is shorter than in the Leiden Roster, in which 
median survival in 800 HD patients was 16.2 (range 2-45) 
years from motor symptom onset [2]. Furthermore, 
disease duration was independent of AAO, which is 
confirmed in our analysis. Another cohort containing 
4,448 DNA samples and 848 detailed disease cases with 
duration data also showed that the CAG repeats number 
determined age at death rather than disease duration [22]. 
Unexpectedly, our median disease duration was far less 
than reported cases in Europe and North America. On the 
one hand, it may be caused by the relatively low standard 
of living condition and lack of access to health-care 
services in the past. On the other hand, this difference may 
be related to uncertainties in AAO ascertainment. 
Frequency of juvenile onset HD cases (AAO <21 
years) and homozygous HD in other studies are 4%-
10%[23-25] and 0.1%-0.4% [26], respectively. In our 
study, the corresponding frequencies were 6.2% (15/242) 
and 0.9% (3/322), which is in a similar range. The lack of 
family history in a subgroup of our cohort, designated to 
uncertain family history, may be due to earlier death of 
the parents [27]. 
In summary, this study presents the clinical 
characteristics and genetic profile of HD in the Han 
Chinese population. This constitutes a solid foundation 
for future clinical, genetic and therapeutic investigation of 
HD in China. However, there are some limitations of this 
study. First, the participants were recruited from three 
centers located at the Southeastern China, thus there might 
be some population bias. Second, because of the low 
prevalence of HD in China, many physicians or even 
general neurologists lack the knowledge for accurate 
diagnosis. As a result, the diagnosis of many patients is 
delayed, and the prevalence of HD and the duration of 
disease is likely to be underestimated. Further studies with 
additional patients are needed for a more comprehensive 
and accurate epidemiological survey of HD in Mainland 
China. 
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